S : aneurysmal dermatofibroma, aneurysmal fibrous histiocytoma, LAMTOR1-PRKCD fusion, next-generation sequencing Aneurysmal fibrous histiocytoma (FH) is an uncommon variant of cutaneous benign FH/dermatofibroma 1 typically presenting as a solitary, pigmented, up to several centimeters in size nodule on extremities or trunk of middle-aged adults. 1,2 Some cases may be clinically concerning for melanoma or vascular neoplasia. 1 The local recurrence rate is approximately 20%, if incompletely excised. 1 Aneurysmal FH is a cellular, poorly demarcated dermal proliferation composed of bland fusiform to rounded mononuclear and multinucleated giant cells distributed haphazardly and in storiform areas 1 with distinctive prominent cleft-like or cavernous blood-filled pseudovascular spaces, hemosiderin deposits, and abundant hemosiderophages. 2 Peripheral collagen trapping, lipidized cells, and discernible mitotic activity are frequent. 1 Its etiopathogenesis is not yet fully understood.We applied next-generation sequencing using TruSeq platform (Illumina, San Diego, California) to perform whole transcriptome sequencing of four aneurysmal FHs ( Figure 1A,B) and one myxoid liposarcoma harboring a known gene fusion (positive control). Transcriptome sequencing data were analyzed by customized bioinformatics pipeline to reveal fusion between late endosomal/lysosomal adaptor and mitogen-activated protein kinase (MAPK) and mammalian target of rapamycin (mTOR) activator 1 (LAMTOR1) and protein kinase C isoform delta (PRKCD) genes in two aneurysmal FH cases ( Figure 1D). The fusion breakpoints were similar and recurrent, fusing the end of exon 1 of LAMTOR1 (11q13.4), with exon 10 of PRKCD (3p21.1) ( Figure 1D). Subsequently, we performed interphase fluorescence in-situ hybridization (FISH) (Abbot Molecular, Vysis, Des Plaines, Illinois) on the initial four and six additional aneurysmal FHs, which showed PRKCD gene rearrangement ( Figure 1C) within the mononuclear and multinucleated cells in the both cases positive by transcriptome sequencing (42% and 38% tumor cells) and one case (34% tumor cells) in the additional set.FISH study failed in one case and was negative in all other cases.Clinical surveillance was available for all patients included in this study (range: 23-60 months; average: 47.6 months). No tumor recurrence was observed in seven proliferations completely removed either at the time of the initial biopsy or subsequent reexcision, or three tumors involving the margins of the initial biopsy that were not reexcised.PRKCD protein is a serine/threonine kinase implicated in tumor promotion, and its catalytic portion has been shown to act as both an anti-and a proapoptotic molecule depending on various factors. 3,4 Even within the same tumor type, the protein may play a contradictory prosurvival or proapoptotic role and it is possible that the gene has different functions at different stages of tumorigenesis. 4 LAM-TOR1 is a highly conserved p18 protein crucial in maintaining cell homeostasis and growth by controlling lysosome...